Skip to content

MaxCyte MXCT Finance Lease Liabilities

Discontinued — last reported Q1 '26

Finance Lease Liabilities at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$8.6M-4.4%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$124K-23.5%
Apyx Medical Corporation logo
Apyx Medical CorporationAPYX
$7K-75.0%
Distribution Solutions Group, Inc. logo
Distribution Solutions Group, Inc.DSGR
$714K-19.0%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's finance lease liabilities?
MaxCyte (MXCT) reported finance lease liabilities of $0 in Q1 2026.
What is the long-term trend for MaxCyte's finance lease liabilities?
Over 5 years (2020 to 2025), MaxCyte's finance lease liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $142.2K to $0.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.